KDR and hepatocellular carcinoma: Examples of these inhibitors include Brivanib (BMS-540215), a dual effect inhibitor of FGFR and VEGFR that has been shown to affect tumor growth in mouse models of human hepatocellular carcinoma (HCC) [33].